Skip to main content

Table 3 Recommendations for stakeholders in SSP buprenorphine services implementation

From: Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation

Health departments

Provide robust support for:

1) Building clinical infrastructure (e.g., health record, billing systems)

2) Developing policies and procedures

3) Addressing medicolegal concerns (e.g., malpractice insurance, legal liability associated with providing clinical services)

4) Selecting and training buprenorphine providers in harm reduction principles

5) Training frontline SSP staff to counsel participants about buprenorphine

Designate a point-person who can provide individualized technical assistance to SSPs

SSPs

Train buprenorphine providers in harm reduction principles and facilitate a system for staff to safely provide feedback on practices

Ensure regular training on buprenorphine for SSP staff

Compensate buprenorphine providers for telehealth visits

Elicit SSP participant input on buprenorphine program design

Develop and update buprenorphine services policies and procedures through collaborative discussion with staff, buprenorphine providers and participants

Designate a dedicated buprenorphine services coordinator

Establish a relationship with a local pharmacy

Link participants to supportive services as needed (housing, mental health services, vocational training, etc.)

Buprenorphine providers

Past experience or dedicated time for training in:

1) Low-threshold treatment principles and practices

2) Harm reduction principles and practices

Work collaboratively with harm reduction staff, particularly:

1) Soliciting and incorporating feedback from team members

2) Identifying and addressing client goals and basic needs